Is kidney injury from Capmatinib reversible?

Reversible. Typical onset: Early — within the first cycles..

How should kidney function be monitored during Capmatinib therapy?

Serum creatinine at baseline and each cycle; cystatin C-based eGFR if a true GFR change is in question; Assessment for peripheral edema at each visit; Liver enzymes and pulmonary symptoms (ILD/pneumonitis) per label.

How can kidney injury from Capmatinib be prevented?

Recognize transporter-mediated pseudo-AKI before acting on the number Use cystatin C-based eGFR if true GFR is uncertain

Who is at higher risk of kidney injury from Capmatinib?

Pre-existing CKD; Concurrent transporter-inhibiting or nephrotoxic drugs.

Back to explorer

Printable monograph

MET inhibitor

Capmatinib

Tabrecta · Capm

MET inhibitor · approved 2020 · 8 citations

Up to date· through 2025

Fairly sourced5/9 · 5 signals

Met: 8 citations
Not met: 12+ references
Not met: Accrued over 10+ years (span: 4y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Met: Current through 2025
Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A MET inhibitor whose creatinine rise and edema are common but usually mild and reversible.

MildMET inhibitor

MET exon 14 skipping NSCLC

§01

Signature kidney injury

Signature lesion

Pseudo-AKI

Representative incidence21%

Increased blood creatinine is a common treatment-related adverse event (~21% in GEOMETRY mono-1; higher in some Asian subsets), and peripheral edema is the single most common adverse event (~47%); most events are grade 1-2 and reversible.Source: Wolf et al., Lancet Oncol 2024

Onset & rechallenge

Time to injurySubacute (~1–6 weeks)

Occurs early, within the first treatment cycles.

Distilled from: “Early — within the first cycles.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Pseudo-AKI#1 · Signatureno population incidence denominator
MET-inhibitor pseudo-AKI: reversible, asymptomatic serum-creatinine rise that recurs on rechallenge while measured GFR (cystatin C, iothalamate clearance) stays stable — reflects blocked tubular creatinine secretion, not true injury (case-documented). PMID 34118303 (opens PubMed in a new tab)
Prerenal / Hemodynamic AKISecondaryqualitative — no citable incidence
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

21%incidence

SeverityMild

ReversibilityReversible

Evidence8 citations

Nephron map

Proximal TubuleBulk reabsorption + drug uptake (OCT2, OATs)

Pseudo-AKI

The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.

§03

Kidney injury

Deep divePseudo-AKI: the creatinine rises and the kidney is fineCreatinine does not only filter — a fifth of it is pushed into the urine by tubular transporters, and a drug that blocks those transporters raises the number without touching the glomerulus, producing a rise that looks like acute kidney injury on every axis except the one that matters.

Mechanism of kidney injury

MET inhibitors raise serum creatinine largely by inhibiting the renal tubular cation transporters that secrete creatinine (MATE1/MATE2-K, OCT2), producing an apparent creatinine increase without a true fall in GFR — a 'pseudo-AKI' transporter effect. Peripheral edema is a separate, characteristic MET-inhibitor class effect (likely vascular/lymphatic).

Clinical presentation

Mild, often early reversible creatinine elevation with a stable cystatin C-based eGFR; frequent peripheral edema, sometimes facial. No active urinary sediment or proteinuria expected with the transporter effect. Nausea and photosensitivity are other common effects.

Management

Usually monitoring; confirm a stable cystatin C before attributing the rise to true AKI or changing dose. Manage edema with supportive measures (limb elevation, diuretics if needed); dose-modify per protocol for grade 3 events or true AKI.Lesion-level management framework

Risk factors

Pre-existing CKD
Concurrent transporter-inhibiting or nephrotoxic drugs

Prevention

Recognize transporter-mediated pseudo-AKI before acting on the number
Use cystatin C-based eGFR if true GFR is uncertain

Anticancer mechanism· how it treats cancer

Selective MET kinase inhibitor; approved for NSCLC with MET exon 14 skipping mutations.

§04

Clinical depth

Renal dose adjustment

No starting-dose adjustment for mild-moderate renal impairment; severe impairment and dialysis are not well studied (use with caution). Dose modifications are driven by edema, ILD/pneumonitis, and hepatotoxicity rather than a CrCl rule.

Dialyzability & ESKD dosing

Highly protein-bound oral small molecule; not expected to be appreciably dialyzed. No validated ESKD dosing.

Differential diagnosis

Transporter-mediated pseudo-AKI (stable cystatin C, bland urine, no oliguria) vs true AKI (prerenal, ATN, AIN). A creatinine rise with a flat cystatin C is the hallmark of the MET-inhibitor transporter effect; peripheral edema here is usually drug-related, not nephrotic.

Monitoring

Serum creatinine at baseline and each cycle; cystatin C-based eGFR if a true GFR change is in question
Assessment for peripheral edema at each visit
Liver enzymes and pulmonary symptoms (ILD/pneumonitis) per label

Key trials & series

GEOMETRY mono-1 (registrational MET exon 14 / MET-amplified NSCLC)
Seto 2021 Japanese GEOMETRY mono-1 subset (higher creatinine-rise rate)

Clinical pearls

Check cystatin C before calling a capmatinib creatinine rise AKI — most are transporter-mediated pseudo-AKI.
Peripheral edema is the single most common AE and is a distinct, often nuisance-level class effect.
Reserve dose changes for true AKI or grade 3 events, not for an isolated creatinine bump with stable cystatin C.

§05

References

6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

6 references · 2021–2025 · 2 since 2023

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 2

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseB · ModerateBrief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.Chen MF et al. · J Thorac Oncol 2024 · PMID 37748692Case series of MATE-1-inhibiting TKIs (including 77 capmatinib patients) showing creatinine retention producing pseudo-AKI, with cystatin-C-based GFR confirming preserved true renal function.CaseC · LimitedCapmatinib-Induced Pseudo-Acute Kidney Injury: A Case Report.Mohan A et al. · Am J Kidney Dis 2022 · PMID 34118303Describes capmatinib causing an asymptomatic serum creatinine rise (pseudo-AKI) with stable cystatin-C/iothalamate GFR, dechallenge/rechallenge confirming the artifact rather than true kidney injury.

FDA label — boxed warning & renal dosing· renal impairment

Quoted verbatim from this agent's current FDA label (Dec 2025) — not paraphrased or interpreted. Full label on DailyMed .

Renal impairment — from the label

No dosage adjustment is recommended in patients with mild (baseline creatinine clearance [CLcr] 60 to 89 mL/min by Cockcroft-Gault) or moderate renal impairment (CLcr 30 to 59 mL/min) [see Clinical Pharmacology (12.3)] . TABRECTA has not been studied in patients with severe renal impairment (CLcr 15 to 29 mL/min).

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 2,345 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 2 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Pseudo-AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.

SIADH / Hyponatremia

ROR 2.8095% CI 1.89–4.15· 25 reports

Electrolyte Disturbance

ROR 1.6095% CI 1.14–2.25· 34 reports

FAERS outcomes & reporting trend· 24.1% of reports w/ death · 16.7% w/ hospitalization

24.1%

Reported with a death outcome

566 of 2,345 reports

16.7%

Reported with hospitalization

391 of 2,345 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 8 systems · 2,345 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 0.7095% CI 0.40–1.24· 12 AKI reports ·no disproportionate AKI reporting signal (CI spans 1).

Renal & urinary

Blood Creatinine Increased66

General / constitutional

Peripheral Swelling288Fatigue261Oedema Peripheral245Oedema134Asthenia113

Gastrointestinal

Nausea241Vomiting85Dysphagia83Diarrhoea62

Respiratory

Dyspnoea141Cough64Pleural Effusion58

Metabolic & electrolyte

Decreased Appetite98

Musculoskeletal

Joint Swelling92

Nervous system

Dizziness74

Skin

Rash49

Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Capmatinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Tepotinib

Tepmetko · MET inhibitor

Profile

Creatinine rise and peripheral edema.

PSEUDOPRE

Mild#1 · 100% phenotype match

Abemaciclib

Verzenio · CDK4/6 inhibitor

Profile

Benign creatinine rise via tubular secretion block.

PSEUDOPRE

Mild#2 · 89% phenotype match

Alectinib

Alecensa · ALK TKI

Profile

Creatinine rise via reduced tubular secretion.

PSEUDOPRE

Mild#3 · 89% phenotype match

Ceritinib

Zykadia · ALK TKI

Profile

GI-driven prerenal AKI.

PREPSEUDO

Mild#4 · 89% phenotype match

Vorasidenib

Voranigo · Mutant IDH1/2 inhibitor

Profile

A brain-penetrant IDH inhibitor whose kidney footprint is a benign creatinine bump, not true AKI.

PSEUDOPRE

Mild#5 · 86% phenotype match

Imlunestrant

Inluriyo · Oral selective estrogen-receptor degrader (SERD)

Profile

2025 brain-penetrant oral SERD; renally benign — the only wrinkle is the benign abemaciclib creatinine rise in the combo.

PSEUDOPRE

Mild#6 · 86% phenotype match

Compare Capmatinib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across ALK / ROS1 / MET / TRK inhibitors

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.